ECQ is a highly unique and undervalued stock that is sure to attract a lot of interest coming into the close of the year.
"Cynata was established to commercialise an outstanding stem cell platform technology, originating from the University of Wisconsin-Madison, a world leader in stem cell research. Cynata plans to develop the technology into an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This would create a new standard in the emergent arena of stem cell therapeutics".
We know that the Wisconsin Research and Alumni foundation has access to FDA APPROVED facilities in the states. There resume is highly impressive and worth a read. An outline of what exactly MCA's are is below:
"Cynata’s core technology revolves around the production of mesenchymoangioblasts (MCAs). MCAs are one of the earliest forms of mesenchymal cell, which go on to produce smooth muscle, bones, cartilage, blood vessels and other tissue types. Immediate opportunities present themselves in the form of treatments for circulatory disorders. The first application targeted for therapies prepared using Cynata’s proprietary MCAs is Critical Limb Ischaemia (CLI) a complication of diabetes. CLI represents a $3bn market. Further development will target other complications of diabetes, other indications involving a loss of circulation or damaged blood vessels and graft-versus-host disease. These conditions represent a combined market worth over $10bn.
A very interesting read on where we are exactly at is highlighted below:
Essentially ECQ's stemcell platform will be fast tracked via the FDA approved facilities. Expect partnership's non dilutive funding and hastening of the trial process. Their technology is in my opinion revolutionary and will attract immediate interest. Given the exposure bio's are getting currently ECQ is in a very good place.
This is a backdoor listing of some great technology. Note the Directors are getting bugger all $$ - Their success is partnered to ECQ share price (200m shares). As I said FDA approved facilities and partnerships will put the fire cracker into this one. Also Washer has had a positive effect recently re isn etc - I expect this to continue. The timing is brilliant.
Wont stay at these prices for long.
ECQ Price at posting:
2.3¢ Sentiment: Buy Disclosure: Held
